Found: 8
Select item for more details and to access through your institution.
Association between immunerelated adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.931429
- By:
- Publication type:
- Article
Development and Validation of Nomograms for Predicting Pneumonia in Patients with COVID-19 and Lung Cancer.
- Published in:
- Journal of Inflammation Research, 2024, v. 17, p. 3671, doi. 10.2147/JIR.S456206
- By:
- Publication type:
- Article
A novel deep learning prognostic system improves survival predictions for stage III non‐small cell lung cancer.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 22, p. 4246, doi. 10.1002/cam4.4782
- By:
- Publication type:
- Article
From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer.
- Published in:
- Journal of Translational Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12967-024-04997-z
- By:
- Publication type:
- Article
From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer.
- Published in:
- Journal of Translational Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12967-024-04997-z
- By:
- Publication type:
- Article
Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs.
- Published in:
- Cancer Management & Research, 2023, v. 15, p. 351, doi. 10.2147/CMAR.S404874
- By:
- Publication type:
- Article
Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer.
- Published in:
- Cancer Management & Research, 2023, v. 15, p. 55, doi. 10.2147/CMAR.S391529
- By:
- Publication type:
- Article
Transformation from Small Cell to Squamous Cell Carcinoma in a Thymic Carcinoma Patient with a Durable Response to Anlotinib: A Case Report.
- Published in:
- Cancer Management & Research, 2022, v. 14, p. 1595, doi. 10.2147/CMAR.S362858
- By:
- Publication type:
- Article